Quinones derived from plant secondary metabolites as anti-cancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 456-463

  Lu, Jin Jian ^a   Bao, Jiao Lin ^a   Wu, Guo Sheng ^a   Xu, Wen Shan ^a   Huang, Ming Qing ^b   Chen, Xiu Ping ^a   Wang, Yi Tao ^a  

^a University of Macau   (Macao)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Plant; Quinone; Secondary metabolites; Tumor

Indexed keywords

ALOE EMODIN; ANTINEOPLASTIC AGENT; BETA LAPACHOL; CHRYSOPHANIC ACID; CISPLATIN; DOXORUBICIN; EMODIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; IMATINIB; JUGLONE; OXALIPLATIN; PACLITAXEL; PLANT MEDICINAL PRODUCT; PLUMBAGIN; PROTEIN BAX; PROTEIN BCL 2; QUINONE DERIVATIVE; RHEIN; SALVICINE; SHIKONIN; THYMOQUINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; BREAST CANCER; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; COLON CANCER; DNA DAMAGE; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; NASOPHARYNX CARCINOMA; NEUROECTODERM TUMOR; NONHUMAN; REVIEW; SKIN CANCER;

EID: 84876706171     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030008     Document Type: Review

References (151)

1. Wang, Z.T.; Liang, G.Y. Zhong Yao Hua Xue. Shanghai Scientific & Technical Publishers, 2009.
2. Wang, J.K.; Li, A.; Wang, H.; Xu, X.Y. Comparative studies on purgative potency among three spieces of certified rhubarb. Zhongguo Zhong Yao Za Zhi, 2006, 31(23), 1987-1991.
3. Padhye, S.; Dandawate, P.; Yusufi, M.; Ahmad, A.; Sarkar, F.H. Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev., 2010, [Epub ahead of print]
4. Aithal, B.K.; Kumar, M.R.; Rao, B.N.; Udupa, N.; Rao, B.S. Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells. Cell Biol. Int., 2009, 33(10), 1039-1049.
5. Krumbiegel, G.; Schulz, H.U. Rhein and aloe-emodin kinetics from senna laxatives in man. Pharmacol., 1993, 47(Suppl 1), 120-124.
6. Agarwal, S.K.; Singh, S.S.; Verma, S.; Kumar, S. Antifungal activity of anthraquinone derivatives from Rheum emodi. J. Ethnopharmacol., 2000, 72(1-2), 43-46.
7. Andersen, D.O.; Weber, N.D.; Wood, S.G.; Hughes, B.G.; Murray, B.K.; North, J.A. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral. Res., 1991, 16(2), 185-196.
8. Arosio, B.; Gagliano, N.; Fusaro, L.M.; Parmeggiani, L.; Tagliabue, J.; Galetti, P.; De Castri, D.; Moscheni, C.; Annoni, G. Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. Pharmacol. Toxicol., 2000, 87(5), 229-233.
9. Kupchan, S.M.; Karim, A. Tumor inhibitors. 114. Aloe emodin: antileukemic principle isolated from Rhamnus frangula L. Lloydia., 1976, 39, (4), 223-224.
10. Pecere, T.; Gazzola, M.V.; Mucignat, C.; Parolin, C.; Vecchia, F.D.; Cavaggioni, A.; Basso, G.; Diaspro, A.; Salvato, B.; Carli, M.; Palu, G. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res., 2000, 60(11), 2800-2804.
11. Suboj, P.; Babykutty, S.; Valiyaparambil Gopi, D.R.; Nair, R.S.; Srinivas, P.; Gopala, S. Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. Eur. J. Pharm. Sci., 2012, 45(5), 581-591.
12. Lin, M.L.; Lu, Y.C.; Su, H.L.; Lin, H.T.; Lee, C.C.; Kang, S.E.; Lai, T.C.; Chung, J.G.; Chen, S.S. Destabilization of CARP mRNAs by aloe-emodin contributes to caspase-8-mediated p53-independent apoptosis of human carcinoma cells. J. Cell Biochem., 2011, 112(4), 1176-1191.
13. Lee, H.Z.; Lin, C.J.; Yang, W.H.; Leung, W.C.; Chang, S.P. Aloe-emodin induced DNA damage through generation of reactive oxygen species in human lung carcinoma cells. Cancer Lett., 2006, 239(1), 55-63.
14. Lin, M.L.; Lu, Y.C.; Chung, J.G.; Li, Y.C.; Wang, S.G.; N, G.S.; Wu, C.Y.; Su, H.L.; Chen, S.S. Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma cells via caspase-8-mediated activation of the mitochondrial death pathway. Cancer Lett., 2010, 291(1), 46-58.
15. Guo, J.M.; Xiao, B.X.; Liu, Q.; Zhang, S.; Liu, D.H.; Gong, Z.H. Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta. Pharmacol. Sin., 2007, 28(12), 1991-1995.
16. Guo, J.; Xiao, B.; Liu, Q.; Gong, Z.; Le, Y. Suppression of C-myc expression associates with anti-proliferation of aloe-emodin on gastric cancer cells. Cancer Invest., 2008, 26(4), 369-374.
17. Xiao, B.; Guo, J.; Liu, D.; Zhang, S. Aloe-emodin induces in vitro G2/M arrest and alkaline phosphatase activation in human oral cancer KB cells. Oral. Oncol., 2007, 43(9), 905-910.
18. Kuo, P.L.; Lin, T.C.; Lin, C.C. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. Life Sci., 2002, 71(16), 1879-1892.
19. Chiu, T.H.; Lai, W.W.; Hsia, T.C.; Yang, J.S.; Lai, T.Y.; Wu, P.P.; Ma, C.Y.; Yeh, C.C.; Ho, C.C.; Lu, H.F.; Wood, W.G.; Chung, J.G. Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. Anticancer Res., 2009, 29(11), 4503-4511.
20. Cardenas, C.; Quesada, A.R.; Medina, M.A. Evaluation of the anti-angiogenic effect of aloe-emodin. Cell Mol. Life Sci., 2006, 63(24), 3083-3089.
21. Chen, Y.Y.; Chiang, S.Y.; Lin, J.G.; Ma, Y.S.; Liao, C.L.; Weng, S.W.; Lai, T.Y.; Chung, J.G. Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int. J. Oncol., 2010, 36(5), 1113-1120.
22. Tabolacci, C.; Lentini, A.; Mattioli, P.; Provenzano, B.; Oliverio, S.; Carlomosti, F.; Beninati, S. Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells. Life Sci., 2010, 87(9-10), 316-324.
23. Fenig, E.; Nordenberg, J.; Beery, E.; Sulkes, J.; Wasserman, L. Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol. Rep., 2004, 11(1), 213-217.
24. Lu, G.D.; Shen, H.M.; Chung, M.C.; Ong, C.N. Critical role of oxidative stress and sustained JNK activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells. Carcinogenesis, 2007, 28(9), 1937-1945.
25. Yeh, F.T.; Wu, C.H.; Lee, H.Z. Signaling pathway for aloe-emodin-induced apoptosis in human H460 lung nonsmall carcinoma cell. Int. J. Cancer, 2003, 106(1), 26-33.
26. Pecere, T.; Sarinella, F.; Salata, C.; Gatto, B.; Bet, A.; Dalla Vecchia, F.; Diaspro, A.; Carli, M.; Palumbo, M.; Palu, G. Involvement of p53 in specific anti-neuroectodermal tumor activity of aloe-emodin. Int. J. Cancer, 2003, 106(6), 836-847.
27. Cha, T.L.; Qiu, L.; Chen, C.T.; Wen, Y.; Hung, M.C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res., 2005, 65(6), 2287-2295.
28. Shi, P.; Huang, Z.; Chen, G. Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am. J. Chin. Med., 2008, 36(4), 805-813.
29. Chun-Guang, W.; Jun-Qing, Y.; Bei-Zhong, L.; Dan-Ting, J.; Chong, W.; Liang, Z.; Dan, Z.; Yan, W. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur. J. Pharmacol., 2010, 627(1-3), 33-41.
30. Chen, Y.Y.; Chiang, S.Y.; Lin, J.G.; Yang, J.S.; Ma, Y.S.; Liao, C.L.; Lai, T.Y.; Tang, N.Y.; Chung, J.G. Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells. Anticancer Res., 2010, 30(3), 945-951.
31. Tan, W.; Lu, J.; Huang, M.; Li, Y.; Chen, M.; Wu, G.; Gong, J.; Zhong, Z.; Xu, Z.; Dang, Y.; Guo, J.; Chen, X.; Wang, Y. Anti-cancer natural products isolated from chinese medicinal herbs. Chin. Med., 2011, 6(1), 27.
32. Lu, C.C.; Yang, J.S.; Huang, A.C.; Hsia, T.C.; Chou, S.T.; Kuo, C.L.; Lu, H.F.; Lee, T.H.; Wood, W.G.; Chung, J.G. Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells. Mol. Nutr. Food Res., 2010, 54(7), 967-976.
33. Cui, X.R.; Takahashi, K.; Shimamura, T.; Koyanagi, J.; Komada, F.; Saito, S. Preparation of 1,8-di-O-alkylaloe-emodins and 15-amino-, 15-thiocyano-, and 15-selenocyanochrysophanol derivatives from aloe-emodin and studying their cytotoxic effects. Chem. Pharm. Bull., 2008, 56(4), 497-503.
34. Li, L.; Chen, P.; Lian, H.K.; Zhao, J.M.; Ma, J.F.; Dong, Z.M. Juglone inhibits the proliferation of human esophageal carcinoma EC1 cells. World Chin. J. Digestol., 2010, 18(11), 1147-1151.
35. Aithal, K.B.; Kumar, S.; Rao, B.N.; Udupa, N.; Rao, S.B. Tumor growth inhibitory effect of juglone and its radiation sensitizing potential: in vivo and in vitro studies. Integr. Cancer Ther., 2011, 11(1), 68-80.
36. Sugie, S.; Okamoto, K.; Rahman, K.M.; Tanaka, T.; Kawai, K.; Yamahara, J.; Mori, H. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett., 1998, 127(1-2), 177-183.
37. Polonik, S.G.; Prokof'eva, N.G.; Agafonova, I.G.; Uvarova, N.I. Antitumor and immunostimulating activity of 5-hydroxy-1,4-naphthoquinone (juglone) o- and s-acetylglycosides. Pharm. Chem. J., 2003, 37(8), 397-398.
38. Mathur, R.; Chandna, S.P.N.K.B.S.D. Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide. Curr. Cancer Drug Tar., 2011, 11(3), 380-392.
39. Seshadri, P.; Rajaram, A.; Rajaram, R. Plumbagin and juglone induce caspase-3-dependent apoptosis involving the mitochondria through ROS generation in human peripheral blood lymphocytes. Free Radic. Biol. Med., 2011, 51(11), 2090-2107.
40. Inbaraj, J.J.; Chignell, C.F. Cytotoxic action of juglone and plumbagin: a mechanistic study using HaCaT keratinocytes. Chem. Res. Toxicol., 2004, 17(1), 55-62.
41. Paulsen, M.T.; Ljungman, M. The natural toxin juglone causes degradation of p53 and induces rapid H2AX phosphorylation and cell death in human fibroblasts. Toxicol. Appl. Pharmacol., 2005, 209(1), 1-9.
42. Ji Yu-Bin, Y.B.; Qu, Z.Y.; Zou, X. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp. Toxicol. Pathol., 2011, 63(1-2), 69-78.
43. Xu, H.L.; Yu, X.F.; Qu, S.C.; Qu, X.R.; Jiang, Y.F.; Sui, D.Y. Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism. Food Chem. Toxicol., 2012, 50(3-4), 590-596.
44. Fila, C.; Metz, C.; van der Sluijs, P. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J. Biol. Chem., 2008, 283(31), 21714-21724.
45. Chao, S.H.; Greenleaf, A.L.; Price, D.H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res., 2001, 29(3), 767-773.
46. Khanal, P.; Namgoong, G.M.; Kang, B.S.; Woo, E.R.; Choi, H.S. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol. Cancer Ther., 2010, 9(3), 606-616.
47. Xu, H.L.; Yu, X.F.; Qu, S.C.; Zhang, R.; Qu, X.R.; Chen, Y.P.; Ma, X.Y.; Sui, D.Y. Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway. Eur. J. Pharmacol., 2010, 645(1-3), 14-22.
48. Bonifazi, E.L.; Rios-Luci, C.; Leon, L.G.; Burton, G.; Padron, J.M.; Misico, R.I. Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol. Bioorg. Med. Chem., 2010, 18(7), 2621-2630.
49. Hussain, H.; Krohn, K.; Ahmad, V.U.; Miana, G.A.; Green, I.R. Lapachol: an overview. Arkivoc, 2007, 2, 145-171.
50. Medeiros, C.S.; Pontes-Filho, N.T.; Camara, C.A.; Lima-Filho, J.V.; Oliveira, P.C.; Lemos, S.A.; Leal, A.F.; Brandao, J.O.; Neves, R.P. Antifungal activity of the naphthoquinone beta-lapachone against disseminated infection with Cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice. Braz. J. Med. Biol. Res., 2010, 43(4), 345-349.
51. Goijman, S.G.; Stoppani, A.O. Effects of beta-lapachone, a peroxide-generating quinone, on macromolecule synthesis and degradation in Trypanosoma cruzi. Arch. Biochem. Biophys., 1985, 240(1), 273-280.
52. Cruz, F.S.; Docampo, R.; Boveris, A. Generation of superoxide anions and hydrogen peroxide from beta-lapachone in bacteria. Antimicrob. Agents Chemother., 1978, 14(4), 630-633.
53. Li, Y.; Sun, X.; LaMont, J.T.; Pardee, A.B.; Li, C.J. Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer. Proc. Natl. Acad. Sci. USA, 2003, 100(5), 2674-2678.
54. Li, C.J.; Li, Y.Z.; Pinto, A.V.; Pardee, A.B. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc. Natl. Acad. Sci. USA, 1999, 96(23), 13369-13374.
55. Dong, Y.; Chin, S.F.; Blanco, E.; Bey, E.A.; Kabbani, W.; Xie, X.J.; Bornmann, W.G.; Boothman, D.A.; Gao, J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin. Cancer Res., 2009, 15(1), 131-139.
56. Suzuki, M.; Amano, M.; Choi, J.; Park, H.J.; Williams, B.W.; Ono, K.; Song, C.W. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat. Res., 2006, 165(5), 525-531.
57. Miao, X.S.; Zhong, C.; Wang, Y.; Savage, R.E.; Yang, R.Y.; Kizer, D.; Volckova, E.; Ashwell, M.A.; Chan, T.C. In vitro metabolism of beta-lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Commun. Mass Sp., 2009, 23(1), 12-22.
58. Li, C.J.; Averboukh, L.; Pardee, A.B. Beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem., 1993, 268(30), 22463-22468.
59. Frydman, B.; Marton, L.J.; Sun, J.S.; Neder, K.; Witiak, D.T.; Liu, A.A.; Wang, H.M.; Mao, Y.; Wu, H.Y.; Sanders, M.M.; Liu, L.F. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Cancer Res., 1997, 57(4), 620-627.
60. Schuerch, A.R.; Wehrli, W. Beta-lapachone, an inhibitor of oncornavirus reverse transcriptase and eukaryotic DNA polymerase-alpha. Inhibitory effect, thiol dependence and specificity. Eur. J. Biochem., 1978, 84(1), 197-205.
61. Lien, Y.C.; Kung, H.N.; Lu, K.S.; Jeng, C.J.; Chau, Y.P. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis. Histol. Histopathol., 2008, 23(11), 1299-1308.
62. Choi, Y.H.; Kim, M.J.; Lee, S.Y.; Lee, Y.N.; Chi, G.Y.; Eom, H.S.; Kim, N.D.; Choi, B.T. Phosphorylation of p53, induction of Bax and activation of caspases during beta-lapachone-mediated apoptosis in human prostate epithelial cells. Int. J. Oncol., 2002, 21(6), 1293-1299.
63. Pink, J.J.; Planchon, S.M.; Tagliarino, C.; Varnes, M.E.; Siegel, D.; Boothman, D.A. NAD(P)H: quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem., 2000, 275(8), 5416-5424.
64. Tagliarino, C.; Pink, J.J.; Dubyak, G.R.; Nieminen, A.L.; Boothman, D.A. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J. Biol. Chem., 2001, 276(22), 19150-19159.
65. Hori, T.; Kondo, T.; Lee, H.; Song, C.W.; Park, H.J. Hyperthermia enhances the effect of beta-lapachone to cause gammaH2AX formations and cell death in human osteosarcoma cells. Int. J. Hyperthermia., 2011, 27, (1), 53-62.
66. Bentle, M.S.; Reinicke, K.E.; Dong, Y.; Bey, E.A.; Boothman, D.A. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res., 2007, 67(14), 6936-6945.
67. Dong, G.Z.; Oh, E.T.; Lee, H.; Park, M.T.; Song, C.W.; Park, H.J. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB. Exp. Mol. Med., 2010, 42, (5), 327-334.
68. Rao, K.V.; McBride, T.J.; Oleson, J.J. Recognition and evaluation of lapachol as an antitumor agent. Cancer Res., 1968, 28(10), 1952-1954.
69. Almeida, E.R.D. Preclinical and Clinical Studies of Lapachol and Beta-Lapachone. Open Nat. Prod. J., 2009, 2, 42-47.
70. L.M, v.d.V. Distribution of plumbagin in the mplumbaginaceae. Phytochemistry, 1972, 11(11), 3247-3248.
71. Luo, P.; Wong, Y.F.; Ge, L.; Zhang, Z.F.; Liu, Y.; Liu, L.; Zhou, H. Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-kappaB activation. J. Pharmacol. Exp. Ther., 2010, 335(3), 735-742.
72. Sun, J.; McKallip, R.J. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk. Res., 2011, 35(10), 1402-1408.
73. Li, J.; Shen, L.; Lu, F.R.; Qin, Y.; Chen, R.; Li, Y.; Zhan, H.Z.; He, Y.Q. Plumbagin inhibits cell growth and potentiates apoptosis in human gastric cancer cells in vitro through the NF-kappaB signaling pathway. Acta. Pharmacol. Sin., 2012, 33(2), 242-249.
74. Subramaniya, B.R.; Srinivasan, G.; Sadullah, S.S.; Davis, N.; Subhadara, L.B.; Halagowder, D.; Sivasitambaram, N.D. Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. PLoS One, 2011, 6(4), e18695.
75. Naresh, R.A.; Udupa, N.; Devi, P.U. Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J. Pharm. Pharmacol., 1996, 48(11), 1128-1132.
76. Kumar, M.R.; Aithal, B.K.; Udupa, N.; Reddy, M.S.; Raakesh, V.; Murthy, R.S.; Raju, D.P.; Rao, B.S. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Drug Deliv., 2011, 18(7), 511-522.
77. Aziz, M.H.; Dreckschmidt, N.E.; Verma, A.K. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res., 2008, 68(21), 9024-9032.
78. Lai, L.; Liu, J.; Zhai, D.; Lin, Q.; He, L.; Dong, Y.; Zhang, J.; Lu, B.; Chen, Y.; Yi, Z.; Liu, M. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br. J. Pharmacol., 2012, 165(4b), 1084-1096.
79. Devi, P.U.; Rao, B.S.; Solomon, F.E. Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J. Exp. Biol., 1998, 36(9), 891-895.
80. Sand, J.M.; Hafeez, B.B.; Jamal, M.S.; Witkowsky, O.; Siebers, E.M.; Fischer, J.; Verma, A.K. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis, 2012, 33(1), 184-190.
81. Hsu, Y.L.; Cho, C.Y.; Kuo, P.L.; Huang, Y.T.; Lin, C.C. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 318(2), 484-494.
82. Kuo, P.L.; Hsu, Y.L.; Cho, C.Y. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol. Cancer Ther., 2006, 5(12), 3209-3221.
83. Wang, C.C.; Chiang, Y.M.; Sung, S.C.; Hsu, Y.L.; Chang, J.K.; Kuo, P.L. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett., 2008, 259(1), 82-98.
84. Gomathinayagam, R.; Sowmyalakshmi, S.; Mardhatillah, F.; Kumar, R.; Akbarsha, M.A.; Damodaran, C. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res., 2008, 28(2A), 785-792.
85. Srinivas, P.; Gopinath, G.; Banerji, A.; Dinakar, A.; Srinivas, G. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol. Carcinog., 2004, 40(4), 201-211.
86. Tian, L.; Yin, D.; Ren, Y.; Gong, C.; Chen, A.; Guo, F.J. Plumbagin induces apoptosis via the p53 pathway and generation of reactive oxygen species in human osteosarcoma cells. Mol. Med. Report., 2012, 5(1), 126-132.
87. Powolny, A.A.; Singh, S.V. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm. Res., 2008, 25(9), 2171-2180.
88. Xu, K.H.; Lu, D.P. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk. Res., 2010, 34(5), 658-665.
89. Ding, Y.; Chen, Z.J.; Liu, S.; Che, D.; Vetter, M.; Chang, C.H. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J. Pharm. Pharmacol., 2005, 57(1), 111-116.
90. Kawiak, A.; Piosik, J.; Stasilojc, G.; Gwizdek-Wisniewska, A.; Marczak, L.; Stobiecki, M.; Bigda, J.; Lojkowska, E. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol. Appl. Pharmacol., 2007, 223(3), 267-276.
91. Sandur, S.K.; Ichikawa, H.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J. Biol. Chem., 2006, 281(25), 17023-17033.
92. Manu, K.A.; Shanmugam, M.K.; Rajendran, P.; Li, F.; Ramachandran, L.; Hay, H.S.; Kannaiyan, R.; Swamy, S.N.; Vali, S.; Kapoor, S.; Ramesh, B.; Bist, P.; Koay, E.S.; Lim, L.H.; Ahn, K.S.; Kumar, A.P.; Sethi, G. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol. Cancer, 2011, 10, 107.
93. Shukla, S.; Wu, C.P.; Nandigama, K.; Ambudkar, S.V. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol. Cancer Ther., 2007, 6(12 Pt 1), 3279-3286.
94. Mathew, R.; Kruthiventi, A.K.; Prasad, J.V.; Kumar, S.P.; Srinu, G.; Chatterji, D. Inhibition of mycobacterial growth by plumbagin derivatives. Chem. Biol. Drug Des., 2010, 76(1), 34-42.
95. Sreelatha, T.; Hymavathi, A.; Babu, K.S.; Murthy, J.M.; Pathipati, U.R.; Rao, J.M. Synthesis and insect antifeedant activity of plumbagin derivatives with the amino acid moiety. J. Agric. Food Chem., 2009, 57(14), 6090-6094.
96. Dandawate, P.; Khan, E.; Padhye, S.; Gaba, H.; Sinha, S.; Deshpande, J.; Venkateswara Swamy, K.; Khetmalas, M.; Ahmad, A.; Sarkar, F.H. Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. Bioorg. Med. Chem. Lett., 2012, 22(9), 3104-3108.
97. Chen, X.; Yang, L.; Oppenheim, J.J.; Howard, M.Z. Cellular pharmacology studies of shikonin derivatives. Phytother. Res., 2002, 16(3), 199-209.
98. Staniforth, V.; Wang, S.Y.; Shyur, L.F.; Yang, N.S. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. J. Biol. Chem., 2004, 279(7), 5877-5885.
99. Wang, Z.; Liu, T.; Gan, L.; Wang, T.; Yuan, X.; Zhang, B.; Chen, H.; Zheng, Q. Shikonin protects mouse brain against cerebral ischemia/reperfusion injury through its antioxidant activity. Eur. J. Pharmacol., 2010, 643(2-3), 211-217.
100. Yang, H.; Zhou, P.; Huang, H.; Chen, D.; Ma, N.; Cui, Q.C.; Shen, S.; Dong, W.; Zhang, X.; Lian, W.; Wang, X.; Dou, Q.P.; Liu, J. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer, 2009, 124(10), 2450-2459.
101. Wu, Z.; Wu, L.; Li, L.; Tashiro, S.; Onodera, S.; Ikejima, T. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J. Pharmacol. Sci., 2004, 94(2), 166-176.
102. Wu, Z.; Wu, L.J.; Li, L.H.; Tashiro, S.; Onodera, S.; Ikejima, T. Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J. Asian Nat. Prod. Res., 2004, 6(3), 155-166.
103. Yeh, C.C.; Kuo, H.M.; Li, T.M.; Lin, J.P.; Yu, F.S.; Lu, H.F.; Chung, J.G.; Yang, J.S. Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). In Vivo, 2007, 21(6), 1011-1019.
104. Yoon, Y.; Kim, Y.O.; Lim, N.Y.; Jeon, W.K.; Sung, H.J. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med., 1999, 65(6), 532-535.
105. Min, R.; Zun, Z.; Min, Y.; Wenhu, D.; Wenjun, Y.; Chenping, Z. Shikonin inhibits tumor invasion via down-regulation of NF-kappaB-mediated MMP-9 expression in human ACC-M cells. Oral. Dis., 2011, 17(4), 362-369.
106. Chang, I.C.; Huang, Y.J.; Chiang, T.I.; Yeh, C.W.; Hsu, L.S. Shikonin Induces Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase Pathway in Osteosarcoma Cells. Biol. Pharm. Bull., 2010, 33(5), 816-824.
107. Min, R.; Tong, J.; Wenjun, Y.; Wenhu, D.; Xiaojian, Z.; Jiacai, H.; Jian, Z.; Wantao, C.; Chenping, Z. Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother. Res., 2008, 22(3), 407-415.
108. Fujii, N.; Yamashita, Y.; Arima, Y.; Nagashima, M.; Nakano, H. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob. Agents Chemother., 1992, 36(12), 2589-2594.
109. Yang, F.; Chen, Y.; Duan, W.; Zhang, C.; Zhu, H.; Ding, J. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int. J. Cancer, 2006, 119(5), 1184-1193.
110. Yao, Y.; Zhou, Q. A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells. Breast Cancer Res. Tr., 2010, 121(1), 233-240.
111. Zhang, Y.; Qian, R.Q.; Li, P.P. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells. Cancer Lett., 2009, 284(1), 47-54.
112. Chen, J.; Xie, J.; Jiang, Z.; Wang, B.; Wang, Y.; Hu, X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene, 2011, 30(42), 4297-4306.
113. Rao, Z.; Liu, X.; Zhou, W.; Yi, J.; Li, S.S. Synthesis and antitumour activity of beta-hydroxyisovalerylshikonin analogs. Eur. J. Med. Chem., 2011, 46(9), 3934-3941.
114. Wu, Y.Y.; Wan, L.H.; Zheng, X.W.; Shao, Z.J.; Chen, J.; Chen, X.J.; Liu, L.T.; Kuang, W.J.; Tan, X.S.; Zhou, L.M. Inhibitory effects of beta,beta-dimethylacrylshikonin on hepatocellular carcinoma in vitro and in vivo. Phytother. Res., 2012, 26(5), 764-771.
115. Kretschmer, N.; Rinner, B.; Deutsch, A.J.; Lohberger, B.; Knausz, H.; Kunert, O.; Blunder, M.; Boechzelt, H.; Schaider, H.; Bauer, R. Naphthoquinones from Onosma paniculata Induce Cell-Cycle Arrest and Apoptosis in Melanoma Cells. J. Nat. Prod., 2012, 75(5), 865-869.
116. Xuan, Y.; Hu, X. Naturally-occurring shikonin analogs--a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett., 2009, 274(2), 233-242.
117. Komi, Y.; Suzuki, Y.; Shimamura, M.; Kajimoto, S.; Nakajo, S.; Masuda, M.; Shibuya, M.; Itabe, H.; Shimokado, K.; Oettgen, P.; Nakaya, K.; Kojima, S. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci., 2009, 100(2), 269-277.
118. Banerjee, S.; Kaseb, A.O.; Wang, Z.; Kong, D.; Mohammad, M.; Padhye, S.; Sarkar, F.H.; Mohammad, R.M. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res., 2009, 69(13), 5575-5583.
119. Sayed-Ahmed, M.M.; Aleisa, A.M.; Al-Rejaie, S.S.; Al-Yahya, A.A.; Al-Shabanah, O.A.; Hafez, M.M.; Nagi, M.N. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid. Med. Cell Longev., 2010, 3(4), 254-261.
120. Chehl, N.; Chipitsyna, G.; Gong, Q.; Yeo, C.J.; Arafat, H.A. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB, 2009, 11(5), 373-381.
121. El-Mahdy, M.A.; Zhu, Q.; Wang, Q.E.; Wani, G.; Wani, A.A. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J. Cancer, 2005, 117(3), 409-417.
122. El-Najjar, N.; Chatila, M.; Moukadem, H.; Vuorela, H.; Ocker, M.; Gandesiri, M.; Schneider-Stock, R.; Gali-Muhtasib, H. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis, 2010, 15(2), 183-195.
123. Kolli-Bouhafs, K.; Boukhari, A.; Abusnina, A.; Velot, E.; Gies, J.P.; Lugnier, C.; Ronde, P. Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest. New Drugs, 2011, [Epub ahead of print]
124. Kaseb, A.O.; Chinnakannu, K.; Chen, D.; Sivanandam, A.; Tejwani, S.; Menon, M.; Dou, Q.P.; Reddy, G.P. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res., 2007, 67(16), 7782-7788.
125. Jafri, S.H.; Glass, J.; Shi, R.; Zhang, S.; Prince, M.; Kleiner-Hancock, H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J. Exp. Clin. Cancer Res., 2010, 29, 87.
126. Gali-Muhtasib, H.; Kuester, D.; Mawrin, C.; Bajbouj, K.; Diestel, A.; Ocker, M.; Habold, C.; Foltzer-Jourdainne, C.; Schoenfeld, P.; Peters, B.; Diab-Assaf, M.; Pommrich, U.; Itani, W.; Lippert, H.; Roessner, A.; Schneider-Stock, R. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res., 2008, 68(14), 5609-5618.
127. Arafa el, S.A.; Zhu, Q.; Shah, Z.I.; Wani, G.; Barakat, B.M.; Racoma, I.; El-Mahdy, M.A.; Wani, A.A. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat. Res., 2011, 706(1-2), 28-35.
128. Lei, X.; Lv, X.; Liu, M.; Yang, Z.; Ji, M.; Guo, X.; Dong, W. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem. Biophys. Res. Commun., 2012, 417(2), 864-868.
129. Woo, C.C.; Loo, S.Y.; Gee, V.; Yap, C.W.; Sethi, G.; Kumar, A.P.; Tan, K.H. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway. Biochem. Pharmacol., 2011, 82(5), 464-475.
130. Hussain, A.R.; Ahmed, M.; Ahmed, S.; Manogaran, P.; Alvi, S.N.; Platanias, L.C.; Al-Kuraya, K.S.; Uddin, S. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free. Radic. Biol. Med., 2011, 50(8), 978-987.
131. Badr, G.; Mohany, M.; Abu-Tarboush, F. Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis., 2011, 10, 236.
132. Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res., 2008, 6(6), 1059-1070.
133. Reindl, W.; Yuan, J.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. Biol., 2008, 15(5), 459-466.
134. Alhosin, M.; Ibrahim, A.; Boukhari, A.; Sharif, T.; Gies, J.P.; Auger, C.; Schini-Kerth, V.B. Anti-neoplastic agent thymoquinone induces degradation of alpha and beta tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest. New Drugs, 2012, 30(5), 1813-1819.
135. Alhosin, M.; Abusnina, A.; Achour, M.; Sharif, T.; Muller, C.; Peluso, J.; Chataigneau, T.; Lugnier, C.; Schini-Kerth, V.B.; Bronner, C.; Fuhrmann, G. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol., 2010, 79(9), 1251-1260.
136. Gurung, R.L.; Lim, S.N.; Khaw, A.K.; Soon, J.F.; Shenoy, K.; Mohamed Ali, S.; Jayapal, M.; Sethu, S.; Baskar, R.; Hande, M.P. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One, 2010, 5(8), e12124.
137. Badr, G.; Lefevre, E.A.; Mohany, M. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS One, 2011, 6(9), e23741.
138. Banerjee, S.; Azmi, A.S.; Padhye, S.; Singh, M.W.; Baruah, J.B.; Philip, P.A.; Sarkar, F.H.; Mohammad, R.M. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm. Res., 2010, 27(6), 1146-1158.
139. Breyer, S.; Effenberger, K.; Schobert, R. Effects of thymoquinone-fatty acid conjugates on cancer cells. ChemMedChem, 2009, 4(5), 761-768.
140. Lown, J.W. The mechanism of action of quinone antibiotics. Mol. Cell. Biochem., 1983, 55(1), 17-40.
141. Meng, L.H.; Ding, J. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta. Pharmacol. Sin., 2007, 28(9), 1460-1465.
142. Zhou, J.; Chen, Y.; Lang, J.Y.; Lu, J.J.; Ding, J. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol. Cancer Res., 2008, 6(2), 194-204.
143. Cai, Y.; Lu, J.; Miao, Z.; Lin, L.; Ding, J. Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells. Cancer Biol. Ther., 2007, 6(11), 1794-1799.
144. Cai, Y.J.; Lu, J.J.; Zhu, H.; Xie, H.; Huang, M.; Lin, L.P.; Zhang, X.W.; Ding, J. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition. Free. Radic. Biol. Med., 2008, 45(5), 627-635.
145. Wang, H.; Mao, Y.; Chen, A.Y.; Zhou, N.; LaVoie, E.J.; Liu, L.F. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry, 2001, 40(11), 3316-3323.
146. Lu, J.J.; Chen, S.M.; Zhang, X.W.; Ding, J.; Meng, L.H. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest. New Drugs, 2011, 29(6), 1276-1283.
147. Dudgeon, D.D.; Shinde, S.; Hua, Y.; Shun, T.Y.; Lazo, J.S.; Strock, C.J.; Giuliano, K.A.; Taylor, D.L.; Johnston, P.A.; Johnston, P.A. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits. J. Biomol. Screen, 2010, 15(7), 766-782.
148. Youns, M.; Efferth, T.; Reichling, J.; Fellenberg, K.; Bauer, A.; Hoheisel, J.D. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem. Pharmacol., 2009, 78(3), 273-283.
149. Mansour, M.A.; Nagi, M.N.; El-Khatib, A.S.; Al-Bekairi, A.M. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochem. Funct., 2002, 20(2), 143-151.
150. Lu, J.J.; Pan, W.; Hu, H.J.; Wang, Y.T. Multi-target drugs: The trend of drug research and development. PLoS ONE, 2012, 7(6), e40262.
151. Petrelli, A.; Giordano, S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem., 2008, 15(5), 422-432.